SPWM
GILD icon

Straight Path Wealth Management’s Gilead Sciences GILD Stock Holding History

Straight Path Wealth Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,706
Closed -$435K – 113
2024
Q4 		$435K Buy
+4,706
New +$424K 0.17% 58

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Straight Path Wealth Management's GILD Position: Q1 2025 in Review

Straight Path Wealth Management sold out of Gilead Sciences (GILD) in Q1 2025, closing a stake of 4,706 shares — an estimated $435K sold.

Straight Path Wealth Management first reported a position in GILD in Q4 2024 and held it in 1 quarter. The position peaked at $435K in Q4 2024. 2,013 funds tracked by Wall St. Rank hold GILD as of Q1 2025.

  • Straight Path Wealth Management reported no remaining Gilead Sciences position as of Q1 2025 after selling out during the quarter.
  • Straight Path Wealth Management sold 4,706 Gilead Sciences shares in Q1 2025, an estimated $435K.
  • Straight Path Wealth Management first reported a position in Gilead Sciences in Q4 2024 and held it in 1 quarter.
  • Straight Path Wealth Management's Gilead Sciences position peaked at $435K in Q4 2024.
  • 2,013 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2025.

Based on Straight Path Wealth Management's 13F filing for Q1 2025, filed 28 Apr 2025.